Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys and Copegus Duration in HCV Genotype 2/3 Non-RVR
NCT00623428Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2008
- Primary completion
- May 2012
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Metabolically Activated Prodrugs
- Countries
- 10
01
Overview
A Phase 3 trial of pegylated interferon alpha, ribavirin in hepatitis C (HCV), sponsored by Roche. Started Jun 2008; status: completed.
02
Drugs
pegylated interferon alpharibavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00623428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00623428.